| Name | Title | Contact Details |
|---|---|---|
Mark Lonergan |
Executive Director of External Manufacturing and Supply Chain Operations | Profile |
Dorothy Pacini |
Director - Human Resources Operations | Profile |
GHX is a software-as-a-service company that`s reducing the cost of doing business in healthcare by automating supply chain processes and improving visibility into the products used in patient care. We`ve built the GHX Global Network, the world`s largest community of healthcare trading partners, connecting supply chain, finance and clinical professionals with their suppliers. Our cloud-based technology makes it easier for customers to drive costs out of the healthcare supply chain. Since 2010, we`ve saved the healthcare industry $5+ billion. Today we`re expanding our solutions to further enhance data management and allow integration of clinical and business systems. The Industry We Serve Our focus is on the healthcare supply chain, through which hospitals and their suppliers buy and deliver the thousands of medical-surgical supplies that clinicians need to effectively care for patients. For most hospitals, supply chain costs are the second largest and fastest growing operational expense, so reining in these costs is imperative. Our Products and Services At the heart of GHX is the GHX Exchange, a platform that connects healthcare providers and suppliers so they can work together electronically. This helps lower costs and simplifies supply chain management by eliminating error-prone, manual order processes. GHX solutions include: • An open and neutral electronic trading exchange • Procurement and accounts payable automation • Content, contract and inventory management • Business intelligence and reporting • Standards enablement and data synchronization
Pointe Scientific is a Canton, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HSI is a Lombard, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Brotoloc Inc is a Eau Claire, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.